Constant Activation of STAT3 Contributes to the Development of Adenomyosis in Females
article
OA: bronze
CC0
⤵ 10 in-corpus citations
AI-generated summary
Constant activation of STAT3 in the endometrium, observed in both mouse models and human samples, drives the development of adenomyosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Adenomyosis is a benign uterine disease that causes dysmenorrhea, heavy menstrual bleeding, and infertility; however, its pathophysiology remains unclear. Since signal transducer and activator of transcription 3 (STAT3) is crucial for endometrial regeneration, we hypothesized that STAT3 participates in adenomyosis pathophysiology. To investigate the influence of STAT3 on adenomyosis development, this study was performed using a novel mouse model of adenomyosis and human specimens of eutopic endometria and adenomyosis lesions. We established a novel mouse model of adenomyosis by puncturing entire mouse uterine layers with a thin needle. Mouse eutopic and ectopic endometria showed a positive immunoreactivity for phosphorylated STAT3 (pSTAT3), the active form of STAT3. Decreased numbers of adenomyotic lesions and reduced expression of Cxcl1, Icam1, and Spp1, which are associated with immune cell chemotaxis and tissue regeneration, were observed in uterine Stat3-deficient mice compared with the controls. In humans, pSTAT3 was intensely expressed at both the eutopic endometrium and the adenomyotic lesions regardless of the menstrual cycle phases. Conversely, it was limitedly expressed in the eutopic endometrium during the menstrual and proliferative phases in women without adenomyosis. Our findings indicate that continuous STAT3 activation promotes adenomyosis development. STAT3 inhibition can be a promising treatment strategy in patients with adenomyosis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (49)
- Adenomyosis and Infertility—Review of Medical and Surgical Approaches via openalex
- A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats. via openalex
- Attenuated monoamine oxidase a impairs endometrial receptivity in women with adenomyosis via downregulation of FOXO1 via openalex
- Decreased Endometrial Expression of Leukemia Inhibitory Factor Receptor Disrupts the STAT3 Signaling in Adenomyosis During the Implantation Window via openalex
- Deficiency of Immunophilin FKBP52 Promotes Endometriosis via openalex
- Endometrial causes of recurrent pregnancy losses: endometriosis, adenomyosis, and chronic endometritis via openalex
- Experimental adenomyosis via openalex
- Four subtypes of adenomyosis assessed by magnetic resonance imaging and their specification via openalex
- Impaired decidualization of human endometrial stromal cells from women with adenomyosis† via openalex
- Pathogenesis of Endometriosis: The Origin of Pain and Subfertility via openalex
- Scribble downregulation in adenomyosis compromises endometrial stromal decidualization by decreasing FOXO1 expression via openalex
- Strain-difference in the induction of adenomyosis by intrauterine pituitary grafting in mice. via openalex
- The induction of adenomyosis in mice by intrauterine pituitary isografts via openalex
- Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations via openalex
- W2148734624 via openalex
- W2174791834 via openalex
- W2204640292 via openalex
- W2236967996 via openalex
- W2345774905 via openalex
- W2413704878 via openalex
- W2616605368 via openalex
- W2692802767 via openalex
- W2759760274 via openalex
- W2799625219 via openalex
- W2807764751 via openalex
- W2808401869 via openalex
- W2809930906 via openalex
- W2893597333 via openalex
- W2981552898 via openalex
- W3002457465 via openalex
- W3087833313 via openalex
- W3094320124 via openalex
- W4313347835 via openalex
- W6632799793 via openalex
- W1488471235 via openalex
- W6701253267 via openalex
- W1984803226 via openalex
- W2016423097 via openalex
- W2018621705 via openalex
- W2026772276 via openalex
- W2053835767 via openalex
- W2072304718 via openalex
- W2085293124 via openalex
- W2099540110 via openalex
- W2099578825 via openalex
- W2103036266 via openalex
- W2104748529 via openalex
- W2134101917 via openalex
- W2135454149 via openalex
Cited by (10)
- Shared Biology Underlying Benign Endometrial Diseases and Endometrial Cancer: Current Knowledge and Future Prospectives 2026
- Prognostic factors of progesterone resistance in symptomatic adenomyosis: impact of lesion localization on treatment outcome of levonorgestrel intrauterine system 2025
- Tongmai Huazheng mixture attenuates adenomyosis by inducing ferroptosis through suppression of the JAK2/STAT3 signaling pathway 2025
- The Role of Platelets in the Pathogenesis and Pathophysiology of Adenomyosis 2023
- Characterising the immune cell phenotype of ectopic adenomyosis lesions compared with eutopic endometrium: A systematic review 2023
- Paradoxical role of phosphorylated STAT3 in normal fertility and the pathogenesis of adenomyosis and endometriosis 2023
- Cracking the enigma of adenomyosis: an update on its pathogenesis and pathophysiology 2022
- Clinical Research Progress of Adenomyosis 2022
- Perioperative Suppression of Schwann Cell Dedifferentiation Reduces the Risk of Adenomyosis Resulting from Endometrial–Myometrial Interface Disruption in Mice 2022
- How does adenomyosis impact endometrial receptivity? An updated systematic review of clinical and molecular insights 2022
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-29T00:34:52.221366+00:00
License: CC0
· commercial use OK